Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The latest updates on our research and how it is improving people’s lives.

Marie Curie Fellowship awarded to Mariana Borsa

Kennedy Main

Congratulations to Mariana Borsa for being awarded the Marie Skłodowska-Curie Actions – Individual Fellowship

Reach for the sky

Kennedy Main

A building project to extend the Kennedy Institute of Rheumatology building with a new floor will create much needed space for the Institute to expand, particularly in the areas of data science and clinical trials.

Kennedy Professor leads Cellular Life Theme of Reuben College

Kennedy Main

Professor Mark Coles was recently appointed to the governing body of the University’s newest graduate college.

Joint cell discovery offers new hope for people with rheumatoid arthritis

Arthritis Kennedy Main

The key to swift treatments to cure the pain of rheumatoid arthritis has been found in the joints of people with the condition who are in long- term remission.

Sir Marc Feldmann awarded the 2020 Tang Prize in Biopharmaceutical Science

Awards Kennedy Main

Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.

Patients with rheumatic pain increasingly turning to opioids


Reporting at EULAR, researchers found that opioid use by patients with rheumatic and musculoskeletal pain was on the rise in Europe.

NDORMS professor awarded prestigious Carol Nachman prize for Rheumatology

Awards Kennedy Main

Christopher Buckley, Kennedy Professor of Translational Rheumatology at the University of Oxford and Birmingham, has been awarded the 2020 Carol Nachman prize for Rheumatology.

New partnership aims to significantly reduce the incidence of hip and vertebral fractures


The Capture the Fracture Partnership aims to prevent 250 million fractures by 2025 and combat the global public health burden of osteoporosis.

NDORMS professors serve on NIHR Urgent Public Health Group


Sion Glyn-Jones and Matt Costa are members of the Covid 19 Urgent Public Health Group coordinating trials to address health impacts of the pandemic.

Oxford leads part of major COVID-19 drugs trial

Main Trials

NDORMS Professor Duncan Richards and Dr Matt Rowland (Nuffield Department of Clinical Neurosciences) are leading the Oxford arm of a new UK trial to investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.

Could do better: clinical trial reporting fails to live up to the mark

Main Research

The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary primary endpoint requires substantial improvement, suggests NDORMS research published in BMC Medicine.

First patient recruit for key drug treatment trial


A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.

New atlas of stromal cells maps out potential for treating human fibrosis

Kennedy Main

Research at the Kennedy Institute reveals sub-populations of stromal cells with distinct functions in human fibrotic disease. These findings could inform development of more specific therapies with fewer off-target effects.

Understanding of inflammatory bowel disease moves a step closer

Kennedy Main

Published in Science Immunology, researchers at the Kennedy Institute have identified the role of IRF5 in controlling intestinal inflammation.

Dr. Michael Dustin joins Strategic Research Collaboration with Cue Biopharma

Kennedy Main

The research will test innovative technology that harnesses the body’s intrinsic immune system to transform the treatment of cancer and autoimmune diseases.

New weapon identified in arsenal against disease

Kennedy Main

Researchers in the Dustin Group reveal supramolecular attack particles are autonomous killing entities released from cytotoxic T lymphocytes

Managing clinical trials during the pandemic

Main Trials

Duncan Richards, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU) is interviewed about clinical trials and the challenges of running them in a pandemic.

The NDORMS response to COVID-19

Botnar Kennedy Main

A number of members of the department are actively helping with the response to the COVID pandemic. Playing a key role in research, literature reviews, clinical trials and engineering projects, all have a shared commitment to collaborate globally to tackle the pandemic.

Load More